Photoreceptors are cells in the retina which convert light into nerve impulses. Because of them, we can see the world around us. The two types of photoreceptors are rod cells and cone cells. Rod cells are responsible for peripheral and night vision, and cone cells are responsible for central and color vision under bright conditions. [Read More]
Pixium Vision reports that follow-up from 18 to 24 months after implantation showed that their PRIMA Bionic Vision System sustainably elicited light perception in all four dry AMD patients with favorable safety profile. Moreover, the second-generation transparent glasses, enabling to combine natural peripheral vision and prosthetic vision, greatly benefited patients and their visual acuity by 3 [Read More]
Degeneration of photoreceptors (rod and cone cells) is a leading cause of vision loss. Since there are no effective treatments to restore vision once photoreceptors are lost, photoreceptor regeneration has the very real prospect of alleviating blindness in these eyes. To that end, a recent innovative study has demonstrated the possibility of reprogramming Müller glial [Read More]
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa Spider-like cells inside the brain, spinal cord and eye hunt for invaders, capturing and then devouring them. These cells, called microglia, often play a beneficial role by helping to clear trash and protect the central nervous system against infection. But a new study [Read More]
Neurotech Pharmaceuticals, Inc. announced on March 30, 2015 that the FDA has approved a Phase 2 clinical study of NT-503 Encapsulated Cell Therapy (ECT) for the treatment of wet age-related macular degeneration (AMD). ECT is an intravitreal implant that is genetically engineered to produce the biologic anti-VEGF drug NT-503 for at least 2 years. ECT, therefore, acts like [Read More]